Twice-daily formulations such as immediate-release exenatide (Byetta) have more specific timing requirements
PlexusDx's Precision Peptide Genetic Test reveals genetic predispositions in oxidative stress and antioxidant pathways
The FDA is evaluating whether regulatory action is necessary after its adverse event reporting system received a growing number of reports of people who used the medications and experienced side effects, such as alopecia (hair loss), aspiration (accidentally breathing in food or liquid), and suicidal thoughts
Wegovy tablets may suit people who: Prefer tablets to injections Are comfortable with a strict morning routine Can wait before eating, drinking or taking other tablets Want a treatment based on semaglutide Are suitable after a clinical assessment Wegovy tablets may be less suitable for people who: Struggle to follow morning medicine routines Need to take other tablets first thing in the morning Have certain stomach, pancreas, gallbladder or thyroid-related medical history Are pregnant, breastfeeding or trying to conceive Are advised by a clinician that GLP-1 treatment is not suitable Foundayo: orforglipron Foundayo contains orforglipron, another oral GLP-1 medicine
It states that clinical eligibility for GLP-1 weight-loss therapy requires BMI of 30 or above, or BMI of 27 or above with a weight-related comorbidity such as hypertension, type 2 diabetes, or cardiovascular disease